<DOC>
	<DOCNO>NCT02130999</DOCNO>
	<brief_summary>Hetlioz™ ( tasimelteon ) use treatment Non-24-Hour-Sleep-Wake Disorder ( Non-24 ) . Non-24 common people totally blind light reset body clock . This cause internal sleep-wake cycle sync 24-hour day-night . Non-24 serious , chronic circadian rhythm disorder blind cause nighttime sleep problem wide range daytime difficulty , include overwhelm urge nap . Tasimelteon give two way ; orally ( mouth ) 20 mg capsule intravenously ( I.V . ) infusion catheter ( injection ) vein . The oral administration approve FDA . The I.V . administration consider investigational approved FDA . This first time tasimelteon give human intravenous ( I.V . ) injection . The purpose research study : - ass quickly single 20 mg oral dose tasimelteon absorb body ; - evaluate single-dose pharmacokinetics tasimelteon single 20 mg oral dose single 2 mg I.V . dose ; - evaluate single-dose pharmacokinetics tasimelteon metabolites single 20 mg oral dose single 2 mg I.V . dose ; - evaluate safety tolerability single 20 mg oral dose tasimelteon ; - evaluate safety tolerability single 2 mg I.V . dose tasimelteon . Pharmacokinetics ( PK ) study drug absorb , distribute , metabolize , eventually eliminate body . Pharmacokinetics body drug . Blood sample take throughout study PK analysis .</brief_summary>
	<brief_title>Open Label Study Assess Absolute Bioavailability Tasimelteon ( HETLIOZ™ )</brief_title>
	<detailed_description />
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Sleep Disorders , Circadian Rhythm</mesh_term>
	<criteria>1 . Men woman age 18 55 year , inclusive ; 2 . Nonsmokers [ abstinence smoking least 6 month screen visit ] test negative cotinine screen baseline ; 3 . Subjects Body Mass Index ( BMI ) ≥18 ≤25 kg/m2 ( BMI = weight ( kg ) / [ height ( ) ] 2 ) ; 4 . Males , nonfecund female ( i.e. , surgically sterilize , procedure do 6 month screen subject postmenopausal , without menses 6 month screen ) , females childbearing potential use acceptable method birth control period 35 day first dose , female must negative pregnancy test screen baseline visit ; Note 1 : Acceptable method birth control include one following : abstinence , vasectomize sexual partner , hormonal method ( i.e . pill , hormonal IUD , DepoProvera , implant , patch , intravaginal device [ NuvaRing ] ) , intrauterine device ( IUD [ copper band coil ] ) , diaphragm , cervical cap , condom spermicidal jelly foam 5 . Vital sign ( 3 minute rest semisupine position ) within range show : 1 . Body temperature 35.037.5 °C ; 2 . Systolic blood pressure 90150 mmHg ; 3 . Diastolic blood pressure 5095 mmHg ; 4 . Pulse rate 50100 bpm . 6 . Ability acceptance provide write informed consent ; 7 . Willing able comply study requirement restriction ; 8 . Subjects must good health determine past medical history , physical examination , electrocardiogram , clinical laboratory test urinalysis ; 1 . History recent ( within six month ) drug alcohol abuse define DSMV , Diagnostic Criteria Drug Alcohol Abuse evidence abuse indicate laboratory assay conduct Screening Visit Baseline ; 2 . Any major surgery within three month first Baseline visit minor surgery within one month ; 3 . History current evidence cardiovascular , hepatic , hematopoietic , renal , gastrointestinal metabolic dysfunction psychiatric disease judge Investigator clinically significant ; 4 . Subjects currently consider suicide risk , subject ever make suicide attempt , currently demonstrate active ( within past 6 month ) suicidal ideation deem Columbia Suicide Severity Rating Scale ( CSSRS ) ; 5 . Any condition require regular use medication except listed Section 8.2 ; 6 . Exposure investigational drug , include placebo , within 30 day 5 halflives ( whichever longer ) baseline 7 . Exposure ( within 2 week Day 1 ) overthecounter medication include melatonin , dietary supplement and/or herbal remedy , except list Section 8.2 ; 8 . Treatment drug know cause major organ system toxicity ( e.g. , chloramphenicol tamoxifen ) 60 day precede Screening visit ; 9 . History intolerance and/or hypersensitivity tasimelteon , and/or drug similar tasimelteon include melatonin ; 10 . Donation loss 400 mL blood within one month prior Baseline Visit ; 11 . Significant illness within two week prior Baseline ; 12 . Pregnant lactating female ; 13 . History porphyria liver disease and/or positive one follow serological result : 1 . A positive hepatitis C antibody test ( antiHCV ) 2 . A positive hepatitis B surface antigen ( HBsAg ) 3 . A positive HIV test result 14 . Use food beverage contain grapefruit grapefruit juice , apple orange juice , vegetables mustard green family ( e.g . kale , broccoli , watercress , collard green , kohlrabi , Brussels sprout , mustard green ) charbroiled meat least 2 week Baseline Visit end study ; 15 . Inability venipunctured and/or tolerate venous access ; 16 . Previous participation BMS214778 , VEC162 , tasimelteon study ; 17 . Subjects unable read speak English ; 18 . Any sound medical reason determine clinical Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Non-24</keyword>
	<keyword>absolute bioavailability</keyword>
	<keyword>tasimelteon</keyword>
	<keyword>Hetlioz™</keyword>
</DOC>